Safety and Immunogenicity of a Candidate Bioconjugate Vaccine Against Streptococcus Pneumoniae When Administered to Adult and Elderly Healthy Subjects. A Phase I Randomized Study.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Bioconjugate-pneumococcal-vaccine-LimmaTech-Biologics (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; First in man
- Sponsors LimmaTech Biologics
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 03 Sep 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 03 Sep 2018 Planned primary completion date changed from 1 May 2018 to 1 Nov 2018.